

## THE CIRCULAR, AS SUPPLEMENTED HEREBY, IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

The definitions and interpretations commencing on page 19 of the Circular referred to below apply throughout this supplement (unless the context indicates a contrary intention).

The Circular, as supplemented hereby, is important and should be read in its entirety, with particular attention to the section entitled "Action required by Adcock Ingram Shareholders", which commences on page 10 of the Circular.

If you are in any doubt as to what action to take, you should consult your Broker, CSDP, banker, accountant or other professional adviser immediately.

If you have disposed of all your Adcock Ingram Shares, please forward the Circular, as supplemented hereby, to the purchaser of such Adcock Ingram Shares or to the Broker, CSDP, banker, accountant or other agent through whom the disposal was effected.

Adcock Ingram and CFR do not accept responsibility, and will not be held liable, for any act of, or omission by, any CSDP or Broker including, without limitation, any failure on the part of a CSDP or Broker or any registered holder of Adcock Ingram Shares to notify the holder of beneficial interests in those shares of the transactions contemplated in the Circular, as supplemented hereby.



### Adcock Ingram Holdings Limited

(Incorporated in the Republic of South Africa)  
Registration number 2007/016236/06  
Share code: AIP ISIN: ZAE000123436  
("Adcock Ingram")



### CFR Pharmaceuticals S.A.

(Incorporated in the Republic of Chile)  
Chilean Tax ID: 76.116.242-K  
Securities Regulation Registry number: 1067  
Share code on the Santiago Stock Exchange: CFR  
ISIN: CL0001762831  
("CFR")

## SUPPLEMENT TO THE COMBINED CIRCULAR TO ADCOCK INGRAM SHAREHOLDERS DATED 18 NOVEMBER 2013 ("the Circular")

The Takeover Regulation Panel has requested that paragraphs 9 and 45 of the Circular be supplemented with the following information:

### 1. Paragraph 9 (ARRANGEMENTS WITH BEE SHAREHOLDERS AND OPTION ARRANGEMENTS)

The Takeover Regulation Panel has requested that at the Combined General Meeting the holders of the A Ordinary Shares and the B Ordinary Shares do not vote the A Ordinary Shares and B Ordinary Shares, respectively.

As already advised in the Firm Intention Announcement of 15 November 2013 and in the Circular, the Adcock Ingram "A" Ordinary Shareholder and the Adcock Ingram "B" Ordinary Shareholder will be required by CFR, pursuant to the "A" Ordinary Agreement and the "B" Ordinary Agreement respectively, not to vote their A Ordinary Shares and B Ordinary Shares respectively, at the Combined General Meeting.

Details of those Adcock Ingram Ordinary Shareholders who provided either irrevocable commitments to vote or a letter of support in relation to the Scheme are set out in paragraph 20 of the Circular.

### 2. Paragraph 45 (DOCUMENTS AVAILABLE FOR INSPECTION)

The TRP has requested that a copy of the letter of support from Prudential Portfolio Managers (South Africa) (Pty) Ltd, referred to in paragraph 20 of the Circular, be made available for inspection during normal business hours at the registered office of Adcock Ingram, from Tuesday, 19 November 2013 up to and including the date of the General Meetings.

Accordingly, Adcock Ingram Shareholders are advised that a copy of that letter will be made available for inspection during normal business hours at the registered office of Adcock Ingram, from Tuesday, 19 November 2013 up to and including the date of the General Meetings.

## INDEPENDENT BOARD RESPONSIBILITY STATEMENT

The Independent Board accepts responsibility for the information contained in this supplement to the Circular which relates to Adcock Ingram and confirms that, to the best of its knowledge and belief, such information which relates to Adcock Ingram is true and this supplement to the Circular does not omit anything likely to affect the importance of such information.

## CFR BOARD RESPONSIBILITY STATEMENT

The CFR Board accepts responsibility for the information contained in this supplement to the Circular which relates to CFR and confirms that, to the best of its knowledge and belief, such information which relates to CFR is true and this supplement to the Circular does not omit anything likely to affect the importance of such information.

## ADCOCK INGRAM BOARD RESPONSIBILITY STATEMENT

The Adcock Ingram Board accepts responsibility for the information contained in this supplement to the Circular which relates to Adcock Ingram and confirms that, to the best of its knowledge and belief, such information which relates to Adcock Ingram is true and this supplement to the Circular does not omit anything likely to affect the importance of such information.

## Adcock Ingram Holdings Limited

### Directors

KDK Mokhele (*Chairperson*)\*, JJ Louw (*Chief Executive Officer*), AG Hall (*Deputy Chief Executive Officer and Financial Director*), M Haus\*<sup>§</sup>, T Lesoli\*, PM Makwana\*, CD Raphiri\*, LE Schönknecht\*, RI Stewart\*, AM Thompson\*  
\*Independent non-executive <sup>§</sup>German

## CFR Pharmaceuticals S.A.

### Directors

Alejandro Weinstein Crenovich (*Chairperson*), Alberto Eguiguren Correa, Juan Bilbao Hormaeche, Juan Antonio Guzmán Molinari, Guillermo Tagle Quiroz, Eliahu Shohet, Nicolás Weinstein Manieu

### Company Secretary

NE Simelane

### Corporate Legal Secretary and Chief Chilean Legal Officer

Agustin Eguiguren

### Registered Office

Adcock Ingram Holdings Limited  
1 New Road  
Midrand, 1682  
(Private Bag X69, Bryanston, 2021)  
South Africa

### Registered Office

CFR Pharmaceuticals S.A.  
Av. Pedro de Valdivia 295  
Providencia 7500524  
Chile CHL

---

## Sponsor

**Deutsche Bank**  
Deutsche Securities (SA) Proprietary Limited  
(A non-bank member of the Deutsche Bank Group)



---

**Date of issue:** 21 November 2013

The Circular and this supplement are available in English only. Copies may be obtained from the registered office of Adcock Ingram and the financial adviser to Adcock Ingram, whose addresses are set out in the “Corporate Information and Advisers” section on page 1 of the Circular, from Thursday, 21 November 2013 until Wednesday, 18 December 2013. Copies may also be found on Adcock Ingram’s website: <http://www.adcock.com>.

**The Circular and this supplement are available in English only. Copies may be obtained from the registered office of Adcock Ingram and the financial adviser to Adcock Ingram, whose addresses are set out in the “Corporate Information and Advisers” section on page 1 of the Circular, from Thursday, 21 November 2013 until Wednesday, 18 December 2013. Copies may also be found on Adcock Ingram’s website: <http://www.adcock.com>.**

The Circular and this supplement, together with a non-official translation thereof into Spanish will be filed, as required by the Chilean Securities Market Law, with the SVS, with a copy provided to all stock exchanges on which CFR’s shares are currently listed in Chile, and published on CFR’s website <http://www.cfr-corp.com>.

The release, publication or distribution of the Circular, as supplemented hereby, in jurisdictions other than South Africa may be restricted by law and, therefore, any persons who are subject to the laws of any jurisdiction other than South Africa should inform themselves about and observe any applicable requirements in those jurisdictions. The information disclosed in the Circular, as supplemented hereby, may not be the same as that which would have been disclosed if the Circular, as supplemented hereby, had been prepared in accordance with the laws and regulations of any jurisdiction other than South Africa.

The Circular, as supplemented hereby, and any accompanying documentation are not intended to, and do not, constitute, or form part of, an offer to sell or an invitation to purchase or subscribe for any securities or a solicitation of any vote or approval in any jurisdiction in which it is unlawful to make such an offer, invitation or solicitation, or such offer, invitation or solicitation would require Adcock Ingram or CFR to comply with disproportionately onerous filing and/or disproportionately onerous regulatory obligations. The Circular, as supplemented hereby, does not constitute a prospectus or a prospectus equivalent document. However, it was accompanied by a prospectus in respect of CFR as it will be constituted after the Scheme. Adcock Ingram Shareholders are advised to read carefully any formal documentation in relation to the Transaction.

**The offer by CFR set out in the Circular, as supplemented hereby, is made for the securities of a South African company, being Adcock Ingram, by means of the Scheme. The offer is subject to disclosure requirements under South African law that are different from those of the United States of America (“US”) and Chile. Financial statements included in the Circular, as supplemented hereby, have been prepared in accordance with South African accounting standards and International Financial Reporting Standards that may not be comparable to the financial statements of US or Chilean companies. It may be difficult for you to enforce your rights and any claim you may have arising under US federal securities laws, since Adcock Ingram is located in South Africa and CFR is located in Chile, and some of their officers and directors reside outside of the US. You may not be able to sue Adcock Ingram and/or CFR or their respective officers or directors in a foreign court, including South African and Chilean courts, for violations of US securities laws. It may be difficult to compel Adcock Ingram and/or CFR and their respective affiliates to subject themselves to a US court’s judgment.**

**You should be aware that CFR may purchase Adcock Ingram Ordinary Shares otherwise than under the Scheme, such as in open market or privately negotiated purchases.**